Yoshihide Asano

15.5k total citations · 1 hit paper
434 papers, 10.3k citations indexed

About

Yoshihide Asano is a scholar working on Pathology and Forensic Medicine, Dermatology and Immunology. According to data from OpenAlex, Yoshihide Asano has authored 434 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 230 papers in Pathology and Forensic Medicine, 142 papers in Dermatology and 112 papers in Immunology. Recurrent topics in Yoshihide Asano's work include Systemic Sclerosis and Related Diseases (195 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (50 papers) and Dermatologic Treatments and Research (49 papers). Yoshihide Asano is often cited by papers focused on Systemic Sclerosis and Related Diseases (195 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (50 papers) and Dermatologic Treatments and Research (49 papers). Yoshihide Asano collaborates with scholars based in Japan, United States and Germany. Yoshihide Asano's co-authors include Shinichi Sato, Hironobu Ihn, Kunihiko Tamaki, Takafumi Kadono, Kenichi Yamane, Masatoshi Jinnin, Makoto Sugaya, Maria Trojanowska, Ayumi Yoshizaki and Koichi Yanaba and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Yoshihide Asano

410 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

2021 142 citations Ayumi Yoshizaki, Shunsuke Miura et al. profile →

Peers

Countries citing papers authored by Yoshihide Asano

Since Specialization

Citations

This map shows the geographic impact of Yoshihide Asano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshihide Asano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshihide Asano more than expected).

Fields of papers citing papers by Yoshihide Asano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshihide Asano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshihide Asano. The network helps show where Yoshihide Asano may publish in the future.

Co-authorship network of co-authors of Yoshihide Asano

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshihide Asano. A scholar is included among the top collaborators of Yoshihide Asano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshihide Asano. Yoshihide Asano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration 2025 ·The Journal of Dermatology ·Emi Yamazaki, Taku Fujimura, Yumi Kambayashi, Manami Takahashi, (unknown), (unknown), Yusuke Muto, Akira Hashimoto, Yoshihide Asano	0
2	Deep learning-based histopathological assessment of tubulo-interstitial injury in chronic kidney diseases 2025 ·Communications Medicine ·(unknown), Kaname Kojima, Silvia Malvica, Kenshi Yamasaki, (unknown), Yuji Oe, Tasuku Nagasawa, Eiji Kondo, (unknown), Setsuya Aiba, Hiroshi Satō, Mariko Miyazaki, Sadayoshi Ito, Mitsuhiro Sato, Tetsuhiro Tanaka, Kengo Kinoshita, Yoshihide Asano, Avi Z. Rosenberg, (unknown), (unknown)	2
3	A Case of Taxane‐Induced Scleroderma Presenting in a Unilateral Upper Limb and a Literature Review 2025 ·The Journal of Dermatology ·(unknown), Takehiro Takahashi, (unknown), (unknown), Hiroshi Mitsui, Taku Fujimura, Setsuya Aiba, Yoshihide Asano	0
4	Recent Advances in Localized Scleroderma 2025 ·SHILAP Revista de lepidopterología ·Toshiya Takahashi, Takehiro Takahashi, Yoshihide Asano	0
5	Nationwide epidemiological and clinical survey of juvenile‐onset morphea in Japan 2025 ·The Journal of Dermatology ·Yasuhito Hamaguchi, Ikuko Ueda‐Hayakawa, Utako Kaneko, Masaki Shimizu, (unknown), Hideki Ishikawa, Ryusuke Ae, Yoshikazu Nakamura, Yoshihide Asano, Manabu Fujimoto	1
6	Atypical bilateral hyperpigmented macules on the lower legs possibly due to cyclophosphamide. 2024 ·Case Reports in Dermatology ·(unknown), Taku Fujimura, Yoshihide Asano	0
7	Characterization of a Cancer-Induced Bone Pain Model for Use as a Model of Cancer Cachexia 2024 ·Current Issues in Molecular Biology ·Takuya Hasegawa, Kohichi Kawahara, Koji Sato, Yoshihide Asano, Takehiko Maeda	2
8	Predictors of clinical features in early‐onset severe systemic sclerosis: An analysis from a multicenter prospective observational Japanese cohort 2024 ·The Journal of Dermatology ·(unknown), Manabu Fujimoto, Yoshihide Asano, Hirahito Endo, Daisuke Goto, Masatoshi Jinnin, Yasushi Kawaguchi, Sumiaki Tanaka, Takahiro Tokunaga, Katsunari Makino, Takashi Matsushita, Sei‐ichiro Motegi, (unknown), (unknown), Minoru Hasegawa	0
9	Eggshell membrane and its major component lysozyme and ovotransferrin enhance the secretion of decorin as an endogenous antifibrotic mediator from lung fibroblasts and ameliorate bleomycin-induced pulmonary fibrosis 2024 ·Biochemistry and Biophysics Reports ·(unknown), Miho Shimizu, (unknown), (unknown), (unknown), (unknown), (unknown), Tomoaki Murakami, Yoshihide Asano, (unknown), Yoriko Atomi	5
10	Biologics for Reducing Cardiovascular Risk in Psoriasis Patients 2023 ·Journal of Clinical Medicine ·H. Terui, Yoshihide Asano	14
11	The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors 2023 ·International Journal of Molecular Sciences ·Ryo Amagai, Toshiya Takahashi, H. Terui, Taku Fujimura, Kenshi Yamasaki, Setsuya Aiba, Yoshihide Asano	11
12	The Contribution of LIGHT (TNFSF14) to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts 2021 ·Journal of Investigative Dermatology ·(unknown), Yohei Ichimura, Takuya Miyagawa, Yuki Fukui, (unknown), (unknown), (unknown), Yuta Norimatsu, (unknown), Ayumi Yoshizaki, Shinichi Sato, Yoshihide Asano	3
13	Increased Regulatory T Cells and Decreased Myeloid-Derived Suppressor Cells Induced by High CCL17 Levels May Account for Normal Incidence of Cancers among Patients with Atopic Dermatitis 2021 ·International Journal of Molecular Sciences ·Sohshi Morimura, Makoto Sugaya, Tomonori Oka, Hiraku Suga, Tomomitsu Miyagaki, Yuichiro Tsunemi, Yoshihide Asano, Shinichi Sato	10
14	Subacute thyroiditis in psoriasis patients treated with biologics targeting tumor necrosis factor‐α and interleukin‐17A, a report of two cases 2020 ·SHILAP Revista de lepidopterología ·Kouki Nakamura, Masahiro Kamata, Shinichi Sato, Yoshihide Asano	1
15	TLR2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation through Decrease in Regulatory T Cells and Impaired IL-10 Production 2020 ·International Journal of Molecular Sciences ·(unknown), Makoto Sugaya, Hideki Fujita, Tomomitsu Miyagaki, Sohshi Morimura, S. Shibata, Yoshihide Asano, Shinichi Sato	23
16	Possible pro‐inflammatory role of heparin‐binding epidermal growth factor‐like growth factor in the active phase of systemic sclerosis 2017 ·The Journal of Dermatology ·Megumi Hirabayashi, Yoshihide Asano, Takashi Yamashita, Shunsuke Miura, Kouki Nakamura, Takashi Taniguchi, Ryosuke Saigusa, Takehiro Takahashi, Yohei Ichimura, Takuya Miyagawa, Ayumi Yoshizaki, Tomomitsu Miyagaki, Makoto Sugaya, Shinichi Sato	6
17	CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells 2017 ·The Journal of Immunology ·Tomonori Oka, Makoto Sugaya, N. Takahashi, Takehiro Takahashi, S. Shibata, Tomomitsu Miyagaki, Yoshihide Asano, Shinichi Sato	55
18	Serum H‐ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosis 2017 ·The Journal of Dermatology ·Takuya Miyagawa, Yoshihide Asano, (unknown), Ryosuke Saigusa, Takashi Taniguchi, Takashi Yamashita, Kouki Nakamura, Megumi Hirabayashi, Shunsuke Miura, Yohei Ichimura, Takehiro Takahashi, Ayumi Yoshizaki, Tomomitsu Miyagaki, Makoto Sugaya, Shinichi Sato	9
19	Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome 2017 ·The Journal of Dermatology ·(unknown), Tomomitsu Miyagaki, Hiroaki Kamijo, Tomonori Oka, N. Takahashi, Hiraku Suga, Ayumi Yoshizaki, Yoshihide Asano, Makoto Sugaya, Shinichi Sato	12
20	Effect of antiinflammatory agents on synthesis of MCP-1/JE transcripts by human blood monocytes. 1992 ·Molecular Pharmacology ·(unknown), H J Gruss, D Riedel, Yoshihide Asano, Steve De Vos, F. Herrmann	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact